Paperpal Prime Logo

Annals of the Rheumatic Diseases : Impact Factor & More

eISSN: 1468-2060pISSN: 0003-4967

Aims and Scope of Annals of the Rheumatic Diseases

The Annals of the Rheumatic Diseases is a peer-reviewed medical journal. It is co-owned by the BMJ Group and the European League Against Rheumatism and covers all aspects of rheumatology, including musculoskeletal conditions, arthritis, and connective tissue diseases. The journal publishes basic, clinical, and translational research and abstracts from conferences. The journal was established in 1939. It is available online by subscription and archived editions of the journal (older than one year) are available free of charge. Each issue, the editor-in-chief selects a paper to be published open access as an "Editors Choice". The editor-in-chief is Josef Smolen. Less

Key Metrics

CiteScore
28.5
Eigenfactor
0.05 - 0.1
H-Index
272
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SJR
Q1Immunology
SNIP
5.22
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Annals of the Rheumatic Diseases

Annals of the Rheumatic Diseases Journal Specifications

Overview
Publisher BMJ PUBLISHING GROUP
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1935
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Annals of the Rheumatic Diseases ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Annals of the Rheumatic Diseases

Effects of air pollution on disease activity in patients with rheumatoid arthritis.
  • 21 Jun 2028
  • Annals of the rheumatic diseases
Development and validation of minimal disease activity, disease flare, and minimal clinically important difference for children with chronic nonbacterial osteomyelitis using a consensus and data-driven approach.
  • 8 Aug 2026
  • Annals of the rheumatic diseases
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.
  • 6 Aug 2026
  • Annals of the rheumatic diseases
EXTL3 dysfunction identified as a driver of aberrant bone development in severe familial ankylosing spondylitis.
  • 6 Aug 2026
  • Annals of the rheumatic diseases
Response to correspondence on 'Progression from symptom onset to rheumatoid arthritis: is the trajectory similar in anticitrullinated protein antibody-positive and -negative disease? A comparative longitudinal study'.
  • 6 Aug 2026
  • Annals of the rheumatic diseases
Air pollution and rheumatoid arthritis disease activity: linking pathogenesis and progression.
  • 5 Aug 2026
  • Annals of the rheumatic diseases
Effects of air pollution on disease activity in patients with rheumatoid arthritis.
  • 21 Jun 2028
  • Annals of the rheumatic diseases
Development and validation of minimal disease activity, disease flare, and minimal clinically important difference for children with chronic nonbacterial osteomyelitis using a consensus and data-driven approach.
  • 8 Aug 2026
  • Annals of the rheumatic diseases
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.
  • 6 Aug 2026
  • Annals of the rheumatic diseases
EXTL3 dysfunction identified as a driver of aberrant bone development in severe familial ankylosing spondylitis.
  • 6 Aug 2026
  • Annals of the rheumatic diseases
Response to correspondence on 'Progression from symptom onset to rheumatoid arthritis: is the trajectory similar in anticitrullinated protein antibody-positive and -negative disease? A comparative longitudinal study'.
  • 6 Aug 2026
  • Annals of the rheumatic diseases
Air pollution and rheumatoid arthritis disease activity: linking pathogenesis and progression.
  • 5 Aug 2026
  • Annals of the rheumatic diseases

FAQs on Annals of the Rheumatic Diseases